Marker Therapeutics, Inc. (MRKR) AI Stock Analysis

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on advancing T cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors across the United States. Established in 1999 and based in Houston, Texas, the company utilizes its proprietary MultiTAA-specific T cell technology to produce non-engineered tumor-specific T cells targeting multiple tumor-associated antigens. Its pipeline includes autologous T cell therapies for lymphoma and solid tumors, allogeneic T cell candidates for acute myeloid leukemia and acute lymphoblastic leukemia, off-the-shelf therapies, and peptide-based vaccines such as TPIV100/110 and TPIV200 for breast and ovarian cancers.

Marker Therapeutics achieved a 5-year revenue compound annual growth rate of 50.0% from FY2020 to FY2025. Annual revenue grew from $1.2M in FY2021 to $3.5M in FY2022 and $6.6M in FY2024, before declining 46.2% to $3.5M in FY2025. Net income was -$41.9M in FY2021, -$29.9M in FY2022, -$8.2M in FY2023, -$10.7M in FY2024, and -$12.2M in FY2025, with an FY2025 operating margin of -363.5%. For the latest quarter ended June 30, 2026, quarterly revenue fell 51.0% year-over-year, while trailing twelve months revenue stood at $3.5M with a profit margin of -245.5%.

As of June 30, 2026, Marker Therapeutics held $11.3M in cash and short-term investments, total assets of $14.6M, and shareholders' equity of $12.2M, with a current ratio of 6.03. In FY2025, operating cash flow was -$12.0M and free cash flow was -$12.0M, with capital expenditures of $1. The company has engaged in significant equity issuance, resulting in a 5-year share count change of 132.3%.

Marker Therapeutics trades at a market capitalization of $17.3M and an enterprise value of $9.3M. The stock has a price-to-sales ratio of 4.9x, compared to 4.1x for the median of its US-listed Healthcare peers, and an EV-to-revenue ratio of 0.2x. Over the past year, MRKR gained 1.0%, while the S&P 500 returned 16.8%. Over a 5-year period, the stock declined 93.5% versus an 83.0% gain for the S&P 500.

Wall Street coverage includes 3 Strong Buy ratings, with zero Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $7.87, representing a 656.4% premium over the last close of $1.04. Consensus estimates project FY2026 revenue of $4.2M and an EPS of -$0.56, followed by FY2027 revenue of $20.2M from 2 analysts. Marker Therapeutics beat EPS estimates in each of the last 4 quarters, and its next earnings date is November 12, 2026.

This page is an AI-written research summary of Marker Therapeutics, Inc. (MRKR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MRKR income statement, MRKR balance sheet, MRKR key metrics, MRKR analyst forecast, MRKR chart. See the MRKR stock overview for the latest quote and news.